Market Place
Sourcing Support
Qurient Launches AML Trial With Adrixetinib (Q702)
24 Oct 2024 //
BUSINESSWIRE
Korea`s Qurient inks agreement with TB Alliance for new anti-tuberculosis agent
06 Feb 2023 //
BIOSPECTRUM ASIA
Qurient and TB Alliance Announce Exclusive License Agreement for Telacebec
03 Feb 2023 //
PR NEWSWIRE
Qurient Announces Dosing of First Patient in Q702 with KEYTRUDA in Ph1b/2 Study
30 Jan 2023 //
BUSINESSWIRE
Qurient Announces Dosing of First Patient in Q901 Phase 1/2 Clinical Study
01 Dec 2022 //
BUSINESSWIRE
Qurient Announces Agreement with MSD to Evaluate Q901 With KEYTRUDA
15 Sep 2022 //
BLOOMBERG
FDA Clears Qurient`s IND Application for Q901 in Cancer Therapy
08 Feb 2022 //
BUSINESSWIRE
Qurient Announces U.S. FDA Clearance of IND Application for Q702
26 May 2020 //
BUSINESSWIRE
Qurient Announces U.S. FDA Clearance of IND Application for Q702
26 May 2020 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.